New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS

P. Ceppi*, M. Papotti, G. Scagliotti

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.

TidsskriftAdvances in Medical Sciences
Udgave nummer1
Sider (fra-til)22-25
Antal sider4
StatusUdgivet - 1. jun. 2010

Fingeraftryk Dyk ned i forskningsemnerne om 'New strategies for targeting the therapy of NSCLC: The role of ERCC1 and TS'. Sammen danner de et unikt fingeraftryk.